Financial Analysis: Nautilus Biotechnology (NASDAQ:NAUT) versus Agilent Technologies (NYSE:A)

Nautilus Biotechnology (NASDAQ:NAUTGet Rating) and Agilent Technologies (NYSE:AGet Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Analyst Ratings

This is a summary of recent recommendations for Nautilus Biotechnology and Agilent Technologies, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nautilus Biotechnology 0 2 2 0 2.50
Agilent Technologies 0 3 9 0 2.75

Nautilus Biotechnology presently has a consensus target price of $8.67, suggesting a potential upside of 151.94%. Agilent Technologies has a consensus target price of $162.90, suggesting a potential upside of 35.33%. Given Nautilus Biotechnology’s higher possible upside, equities analysts clearly believe Nautilus Biotechnology is more favorable than Agilent Technologies.

Earnings and Valuation

This table compares Nautilus Biotechnology and Agilent Technologies’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nautilus Biotechnology N/A N/A -$50.31 million ($0.57) -6.04
Agilent Technologies $6.32 billion 5.72 $1.21 billion $3.94 30.55

Agilent Technologies has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.


This table compares Nautilus Biotechnology and Agilent Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nautilus Biotechnology N/A -15.57% -14.77%
Agilent Technologies 18.70% 27.04% 13.09%

Insider and Institutional Ownership

47.9% of Nautilus Biotechnology shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.


Agilent Technologies beats Nautilus Biotechnology on 9 of the 11 factors compared between the two stocks.

About Nautilus Biotechnology (Get Rating)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

About Agilent Technologies (Get Rating)

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with's FREE daily email newsletter.